Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5571001 | 1.00 | CYP19A1 (0.48) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL5048062 | 1.00 | CYP19A1 (0.48) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1180028 | 0.91 | CYP19A1 (0.49) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL5569832 | 0.84 | DRD2 (0.48) | CYP11B2CYP11B1CYP17A1HRH3 | |
| SCHEMBL5572854 | 0.82 | CYP19A1 (0.43) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL5573400 | 0.82 | CYP17A1 (0.42) | CYP17A1 | |
| SCHEMBL5573376 | 0.82 | CYP17A1 (0.42) | CYP11B2CYP17A1 | |
| SCHEMBL27285097 | 0.82 | CYP17A1 (0.42) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL5573406 | 0.82 | CYP17A1 (0.44) | CYP19A1CYP17A1 | |
| SCHEMBL27285101 | 0.82 | CYP17A1 (0.42) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076784-A1 | Bicyclic, Nitrogen-Containing Heterocycles and Aromatase Inhibitors | NOVARTIS AG (CH) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076784-A1 | Bicyclic, Nitrogen-Containing Heterocycles and Aromatase Inhibitors | CYP19A1, NR5A1, HSD17B11 | CYP19A1 1/4885CYP11B2 6/4885CYP11B1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.